Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development. Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in ...

Fate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...

Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Fate Therapeutics Inc. faces significant volatility in its stock price, independent of its ...

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on May 6. Gil Blum has given his Hold rating due to a combination of factors concerning Fate ...

Fate Therapeutics (NASDAQ:FATE – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports.

Fate Therapeutics (FATE) has shared an announcement. Fate Therapeutics, Inc. has announced the appointment of J. Scott Wolchko as the new Chief Financial Officer and principal financial and accounting ...